Skip to main content

Month: May 2020

Xebec accueille M. Peter Bowie à titre de conseiller de son conseil d’administration

MONTRÉAL, 11 mai 2020 (GLOBE NEWSWIRE) — Xebec Adsorption Inc. (TSXV: XBC) (« Xebec »), fournisseur mondial de solutions d’énergie propre, a annoncé aujourd’hui que M. Peter Bowie deviendra conseiller de son conseil d’administration et sa direction en matière de stratégie, de finance d’entreprise et de vérification. Il sera également nommé au conseil d’administration de la société lors de l’assemblée générale annuelle en juin.M. Bowie est actuellement membre du conseil d’administration et du comité de vérification de Magna International Inc. Il apporte une expertise financière, un engagement envers l’excellence en matière de gouvernance et de vérification, une solide compréhension de la stratégie et du risque, ainsi qu’une vision détaillée de la dynamique politique et économique en Chine.Il a été directeur général de Deloitte Chine...

Continue reading

Daré Bioscience and Health Decisions Form Strategic Partnership to Accelerate the Development of Daré’s Novel Pipeline of Women’s Health Programs

SAN DIEGO AND DURHAM, N.C., May 11, 2020 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, and Health Decisions, Inc., a full-service contract research organization (CRO) specializing in women’s health clinical research and diagnostic development, today announced that the companies have signed a partnership agreement under which Health Decisions will exclusively provide CRO services within the United States to support the clinical development of Daré’s innovative pipeline of novel programs designed specifically to address persistent unmet needs in the areas of contraception, fertility, and broader gynecological disorders. Daré and Health Decisions have successfully worked together on prior Daré clinical studies, including the post-coital test clinical study of Ovaprene®. The partnership...

Continue reading

SurveyMonkey Hosts Third Annual Virtual Curiosity Conference

SAN MATEO, Calif., May 11, 2020 (GLOBE NEWSWIRE) — WHAT: SurveyMonkey (Nasdaq: SVMK) is hosting its third annual virtual Curiosity Conference to share how to enhance customer experience and use survey best practices and feedback to stay connected to customers and employees during these uncertain times. The virtual conference will feature thought-provoking general sessions to help organizations understand how to stay connected as the situation evolves, as well as profession-specific tracks for marketing, HR, CX, Market Research, and Education.SurveyMonkey’s mission is to power the curious and this conference is designed to help organizations around the world to transform feedback into business intelligence.WHO: SurveyMonkey CEO Zander Lurie, Gainsight CEO Nick Mehta, Upwork CEO Hayden Brown, Nasdaq President Nelson Griggs, and ESPN...

Continue reading

Histogen Receives US FDA IND Approval to Initiate Phase 1b/2a Trial of HST 001 in Androgenic Alopecia

SAN DIEGO, May 11, 2020 (GLOBE NEWSWIRE) — Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for HST 001, the Company’s lead therapeutic candidate for the treatment of androgenic alopecia in men.Under this IND, Histogen intends to initiate a Phase 1b/2a clinical trial of HST 001, a Hair Stimulating Complex (HSC), in the second quarter of 2020.  This clinical trial is designed to assess the safety, tolerability and efficacy of HST 001, as well as determine optimal dosing in male pattern hair loss. Start-up activities are currently underway to include clinical study site preparation and subject screening.“The FDA acceptance of our...

Continue reading

Savaria Announces Two Contracts Totaling $3 Million Home Elevators to “Stay At Home With Savaria”

LAVAL, Québec, May 11, 2020 (GLOBE NEWSWIRE) — Savaria Corporation (“Savaria”) (TSX: SIS) one of the global leaders in the accessibility industry, today announced the recent signing of sales contracts with two major home builders by way of Savaria’s direct sales offices located in Toronto (Ontario, Canada) and in Baltimore (Maryland, USA). The combined value of the contracts is approximately $3 million (CAD).In the Toronto area, a well-regarded builder has committed to purchase 50 home elevators from Savaria, and in the Baltimore region, an award-winning builder has agreed to purchase 43 Savaria home elevators. Both projects will start in the coming months, with Savaria’s direct sales offices providing installation services.“These two contracts reflect the potential for Savaria in the coming years. We have long been aware that baby...

Continue reading

Savaria annonce deux contrats d’ascenseurs résidentiels « Restez à la maison avec Savaria » pour un montant total de 3 millions de dollars

LAVAL, Québec, 11 mai 2020 (GLOBE NEWSWIRE) — Corporation Savaria (« Savaria ») (TSX : SIS) un des chefs de file mondiaux de l’industrie de l’accessibilité, annonce aujourd’hui avoir signé récemment des contrats de vente avec deux entrepreneurs résidentiels d’importance. Ces contrats ont été signés par le biais des bureaux de vente directe de Savaria situés à Toronto (Ontario, Canada) et à Baltimore (Maryland, États-Unis). La valeur combinée des contrats s’élève approximativement à 3 millions de dollars (CAD).Dans la région de Toronto, un entrepreneur réputé s’est engagé à acheter 50 ascenseurs résidentiels et dans la région de Baltimore, un entrepreneur lauréat a également accepté d’acheter 43 ascenseurs résidentiels de Savaria. Les deux projets débuteront dans les prochains mois et les bureaux de vente directe de Savaria fourniront...

Continue reading

Avenue Therapeutics Reports First Quarter 2020 Financial Results and Recent Corporate Highlights

NEW YORK, May 11, 2020 (GLOBE NEWSWIRE) — Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today reported financial results and recent corporate highlights for the first quarter ended March 31, 2020.“In the first quarter of 2020, the U.S. Food and Drug Administration (“FDA”) accepted our IV tramadol New Drug Application (“NDA”) submission for review and set a Prescription Drug User Fee Act (“PDUFA”) goal action date of October 10, 2020,” stated Lucy Lu, M.D., Avenue’s President and CEO. “2020 is gearing up to be an exciting year for Avenue as we anticipate that the merger with InvaGen Pharmaceuticals Inc., a subsidiary of Cipla Limited, will be completed shortly after the PDUFA date, pending a positive outcome and other certain conditions...

Continue reading

Front Yard Residential Corporation Reports First Quarter 2020 Results

CHRISTIANSTED, U.S. Virgin Islands, May 11, 2020 (GLOBE NEWSWIRE) — Front Yard Residential Corporation (“Front Yard” or the “Company”) (NYSE: RESI) today announced its financial and operating results for the first quarter of 2020.First Quarter 2020 Highlights and Recent DevelopmentsSettled the termination of the previously announced merger agreement with Amherst Residential, LLC (“Amherst”), pursuant to which Amherst agreed to pay a $25 million termination fee, purchase 4.4 million shares of Front Yard common stock in a primary issuance at $12.50 per share for an aggregate purchase price of $55 million and provide a $20 million committed two-year unsecured loan facility to Front Yard.Rental revenues increased to $54.3 million for the first quarter of 2020, up 4.3% over the fourth quarter of 2019.The first quarter of 2020 was Front...

Continue reading

Altisource Asset Management Corporation Reports First Quarter 2020 Results

CHRISTIANSTED, U.S. Virgin Islands, May 11, 2020 (GLOBE NEWSWIRE) — Altisource Asset Management Corporation (“AAMC” or the “Company”) (NYSE American: AAMC) today announced financial and operating results for the first quarter of 2020.First Quarter 2020 Highlights and Recent DevelopmentsIncreased Front Yard Residential Corporation’s (“Front Yard”) rental revenues to $54.3 million for the first quarter of 2020, up 4.3% over the fourth quarter of 2019.Managed continued improvement in Front Yard’s operating metrics, yielding its best ever quarterly operational results.Advised Front Yard in the sale of 82 non-core homes for a $1.5 million gain over carrying value.Negotiated the settlement by Front Yard, at the direction of the Front Yard Board, to terminate the previously announced merger agreement with Amherst Residential,...

Continue reading

Orgenesis First Quarter 2020 Revenue Increases 348% to $1.9 Million Reflecting Success of CGT Biotech Platform

GERMANTOWN, Md., May 11, 2020 (GLOBE NEWSWIRE) — Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering, global biotech company committed to accelerating commercialization and transforming the delivery of cell and gene therapies (CGTs) while lowering costs, today reported financial results for the first quarter ended March 31, 2020.First Quarter 2020 Financial Highlights:Revenue increased 348% to $1.9 million compared to $0.4 million for the first quarter ended March 31, 2019Achieved net income of $75.6 million, or $4.23 per share, reflecting sale of MasthercellCash and cash equivalents were $107.1 million as of March 31, 2020Vered Caplan, CEO of Orgenesis, commented, “Step by step, our CGT Biotech Platform is gaining traction within the market, as illustrated by the year-over-year growth.  In the first quarter...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.